



Guidance for storing and travelling with **AMGEVITA^{®1}**



Useful guidance and tips on how
to properly store and transport
your AMGEVITA.


AMGEVITA should be stored in a refrigerator (between 2°C and 8°C) at all times. This includes when transporting from the pharmacy or when travelling.



For more information on travelling with medicines and medical devices **scan the QR code**. Remember to also check the requirements and limitations for the country you are travelling to.



Storing AMGEVITA



Always store AMGEVITA between 2°C to 8°C. When transporting AMGEVITA, you will need to use an insulated container. A hard-walled insulated container is preferable, but you can also use a cooler bag.



Do not freeze AMGEVITA. Do not use the syringe or pen if the solution has been frozen (even if it has thawed).



Do not use AMGEVITA if it has been stored at room temperature (below 25°C) for longer than 14 days. Do this even if it has been returned to the refrigerator.



Store AMGEVITA out of direct sunlight. Keep AMGEVITA in the packaging until it is time to use it. This will help protect it from the light.



Do not shake AMGEVITA. Use a new AMGEVITA pen or syringe if it has been shaken or dropped on a hard surface.

If you are concerned about the effect of temperature on your AMGEVITA, contact your pharmacist, healthcare provider or Amgen Medical Information on **0800 443 885** or email: **MEDINFO.JAPAC@amgen.com**.

Travelling with AMGEVITA



When needed, store your AMGEVITA pens or syringes at room temperature (below 25°C) for a maximum of 14 days. Be sure to protect it from the light.



If it is not used within 14 days of storage at room temperature, AMGEVITA must be discarded, even if it has been returned to the refrigerator.



Write down the date you first removed the AMGEVITA pen or syringe from the refrigerator on the pack leaflet so you can check how long it has been stored out of the refrigerator.



If you will be travelling for more than 14 days, you must be able to store your AMGEVITA in a refrigerator between 2°C to 8°C.



As soon as you arrive at your destination, place your AMGEVITA in the refrigerator. If this is not possible, keep your AMGEVITA in the cooling container with an ice brick.



Do not leave AMGEVITA in a parked car as it might become too hot.

Air travel with AMGEVITA



Carry a letter from your healthcare provider detailing the medication and quantity you will be carrying with you on the flight as well as **the need for an ice brick**. This may be necessary due to liquid restrictions on some airlines. You can download a letter from the AMGEVITA website by scanning the QR code below, or talk to your healthcare provider.



Transporting AMGEVITA in a **hard-walled insulated container rather than a cooler bag** will help maintain the cool temperature required.



Keep the insulated container with you as cabin baggage.

For more information, to report a side effect involving AMGEVITA or a product complaint contact Amgen Medical Information on **0800 443 885** or email: **MEDINFO.JAPAC@amgen.com**.

IMPORTANT INFORMATION ABOUT AMGEVITA: AMGEVITA® is a prescription medicine containing adalimumab. AMGEVITA is available as single use pre-filled syringe(s) (containing 20 mg or 40 mg adalimumab) or single-use pre-filled pens (containing 40 mg adalimumab). AMGEVITA is a biosimilar medicine comparable to Humira®. *What AMGEVITA is used for:* AMGEVITA is used to reduce inflammation in patients with some inflammatory diseases, including rheumatoid arthritis, polyarticular juvenile idiopathic arthritis, enthesitis-related arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, non-radiographic axial spondyloarthritis, Crohn's disease, ulcerative colitis, hidradenitis suppurativa, and uveitis. **AMGEVITA has risks and benefits.** *Do not use AMGEVITA if you have:* an allergy to any medicines containing adalimumab or any of the other ingredients in AMGEVITA; a severe infection; tuberculosis (known as TB); moderate-severe heart failure; or if using a medicine containing abatacept (Orencia®) or anakinra. *Before you use AMGEVITA tell your doctor if you have:* a current infection or a history of infections that keep coming back (including TB, hepatitis B, fungal or any other infection); any conditions that increase the risk of infections; had close contact with someone with TB, or Hepatitis B virus (HBV) or are a carrier of HBV; conditions that affect protective nerve layers, such as multiple sclerosis; blood disorders; low resistance to infections or diseases; any serious heart conditions or cancers; disorders that occur when the immune system attacks and destroys healthy cells, tissues, or organs by mistake; lung diseases that make breathing difficult; inflammation of the middle layer of the eye (uveitis); kidney or liver problems; psoriasis (a type of skin disease) and have undergone phototherapy; or if you have any allergies. Your risk of getting serious infections or certain kinds of cancer may increase if you take AMGEVITA. In rare cases, these infections may be life-threatening. Tell your doctor if you are pregnant or plan to become pregnant, or if you are breastfeeding or plan to. *Tell your doctor immediately or go to your nearest hospital if you develop symptoms:* of an allergic reaction, such as chest tightness, shortness of breath or difficulty breathing, swelling of the face, lips or tongue, or a rash; heart problems, such as shortness of breath with exertion or lying down, swollen feet; or signs of blood disorders, such as a persistent fever, bruising, bleeding easily, paleness. Tell your doctor straight away if: symptoms of TB or any other infection appear during treatment (such as fever, persistent cough, weight loss, listlessness or lack of energy, skin sores, problems with your teeth and gums, burning when you pass urine, etc); you develop cancer, skin lesions (new skin spots or sores), or if existing lesions change appearance; nervous system disorders (such as numbness, or tingling, arm or leg weakness, double vision). Tell your doctor straight away if you become pregnant while using AMGEVITA. If you use AMGEVITA during pregnancy, your baby may have a higher risk of getting an infection. It is important that you tell your baby's doctors and other healthcare professionals about your AMGEVITA use during your pregnancy before the baby receives any vaccine. *Tell your doctor and other healthcare professionals:* if you are taking any other medicines, including any that you get without a prescription; if you are going to have surgery, or if you are scheduled for any vaccines. Patients taking AMGEVITA should not receive live vaccines. Tell all doctors, dentists, and pharmacists who are treating you that you are using AMGEVITA. *Common Side Effects:* Tell your doctor if you experience any side effects that make you feel unwell. The most common side effects of this medicine are injection site reactions (e.g. pain, swelling, redness); respiratory tract infections; ear or eye pain, inflammation of the eye or eye lid; mouth ulcers, pain or bleeding from the gums; burning or pain when passing urine or blood in the urine; skin bumps or sores that don't heal; headache or migraine, dizziness; muscle weakness or numbness; tummy pain, nausea, vomiting, reflux or heartburn; chest pain; rash, itching; finger or toe nail problems; hair loss; tiredness; muscle, joint or bone pain; bleeding or bruising more easily; depression or anxiety; increased heart rate; and infections caused by viruses, bacteria or fungi. Your doctor might also tell you about abnormal laboratory test results, such as reduced blood cell counts for example. **Use strictly as directed. Please read the safety information in the AMGEVITA Consumer Medicines Information (CMI), available at www.medsafe.govt.nz/consumers/cmi or telephone 0800 443 885 (free call).** If you have any questions about using AMGEVITA, or if symptoms continue, or you have side effects, speak to your healthcare professional.

AMGEVITA is fully funded for most of the above conditions (under Special Authority) except for enthesitis-related arthritis and non-radiographic axial spondyloarthritis. Normal pharmacy prescription and doctor's charges will apply. Amgen (New Zealand) Limited, Auckland, New Zealand. Telephone: 0800 443 885. E-mail medinfo.JAPAC@amgen.com. VI. TAPS MR797.

Reference: 1. AMGEVITA Consumer Medicines Information.

©2023 Amgen. All rights reserved. Amgen (New Zealand) Limited, Level 22, PwC Tower, 15 Customs Street West, Auckland 1010. Telephone: 0800 443 885 | Email: medinfo.JAPAC@amgen.com. NZL-501-1223-80002. TAPS MR9906. Date of preparation: April 2024. AMG-13184.